Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.20 +0.84 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
59 60 Next >
Face Of US COVID-19 Response, Dr Anthony Fauci To Retire In December
  
Via Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
3 Top Stocks to Invest In Right Now
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
Benzinga Before The Bell: Elon Musk May Get Info It Wants From Twitter, Apple To Lay Off 100 Recruiter Contractors, Saudi's Investment Fund Picks Stocks Of US Big Tech And Other Top Financial Stories Tuesday, August 16
Reuters 
Via Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
Via Benzinga
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
Via Benzinga
Benzinga Before The Bell: YouTube Plans Streaming Marketplace, Drug Pricing Bill Passes Congress, Bitcoin Could Surge To All-Time High Soon And Other Top Financial Stories Monday, August 15
Reuters PlayAGS Shares Pop Premarket On Takeover Offer At 33% Premium 
Via Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year... 
Via Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Blue Water Vaccines: Early Stage Developer Of Infectious Disease Vaccines
Is BWV a buy? We sat down with Blue Water Vaccines management to find out what the company has been up to and what have in store for the future. 
Via Talk Markets
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Via Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment
Valneva SE (NASDAQ: VALN) is trying to come back after a disappointing COVID-19 shot by betting on the Lyme disease vaccine. Climate change is spurring more cases of tick-borne Lyme disease.  
Via Benzinga
The Power of Science to Stop a Killer
Via Investor Brand Network
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that... 
Via Benzinga
The Power of Science to Stop a Killer
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114... 
Via FinancialNewsMedia
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
Via Benzinga
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
From AstraZeneca
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.